Retrospective comparisons of nanoparticle albumin-bound paclitaxel and docetaxel neoadjuvant regimens for breast cancer-Reference-Cited by-同舟云学术

Retrospective comparisons of nanoparticle albumin-bound paclitaxel and docetaxel neoadjuvant regimens for breast cancer

Published:2021-02 Issue:5 Volume:16 Page:391-400
ISSN:1743-5889
Container-title:Nanomedicine
language:en
Short-container-title:Nanomedicine

Author:

Li Yan¹^ORCID,Chen Xiang²,Zhu Qiannan¹,Chen Rui¹,Xu Lu³,Li Shuo¹,Shi Xiaoqing¹,Xu Haiping¹,Xu Yinggang¹,Zhang Weiwei¹,Huang Xiaofeng¹,Zha Xiaoming¹⁴^ORCID,Wang Jue¹⁴

Affiliation:

1. Department of Breast Disease, the First Affiliated Hospital of Nanjing Medical University, Nanjing 210000, PR China

2. Department of Thyroid and Mammary Gland Surgery, Yixing People’s Hospital, Wuxi 214200, PR China

3. Department of Clinical Nutrition, First Affiliated Hospital of Nanjing Medical University, Nanjing 210000, PR China

4. Collaborative Innovation Center for Cancer Personalized Medicine, Nanjing Medical University, Nanjing 210000, PR China

Abstract

Aim: To compare the efficacy and safety of 2-weekly nanoparticle albumin-bound paclitaxel (nP) and 3-weekly docetaxel regimens as neoadjuvant systemic therapy (NST) for breast cancer. Materials & methods: Patients (n = 201) received NST comprising either dose-dense epirubicin and cyclophosphamide followed by 2-weekly nP (n = 104) or 3-weekly courses of epirubicin and cyclophosphamide followed by docetaxel (n = 97). Results: Higher pathological complete response rates were achieved by the nP group. Subgroup analysis showed that the nP-based regimen achieved higher pathological complete response rates in patients with triple-negative tumor cells and high Ki67 levels. However, grades 3–4 peripheral sensory neuropathies were more frequent in the nP group. Conclusion: The 2-weekly nP-based regimen might be a better choice of NST for patients with breast cancer.

Publisher

Future Medicine Ltd

Subject

Development,General Materials Science,Biomedical Engineering,Medicine (miscellaneous),Bioengineering

Link

https://www.futuremedicine.com/doi/pdf/10.2217/nnm-2020-0458

Reference37 articles.

1. Recommendations from an international expert panel on the use of neoadjuvant (primary) systemic treatment of operable breast cancer: new perspectives 2006

2. National Comprehensive Cancer Network. National Comprehensive Cancer Network Guidelines (requires sign-in). https://www.nccn.org/professionals/physician_gls/pdf/breast.pdf.

3. If there is no overall survival benefit in metastatic breast cancer: Does it imply lack of efficacy? Taxanes as an example

4. PELICAN-IPC 2015-016/Oncodistinct-003: A Prospective, Multicenter, Open-Label, Randomized, Non-Comparative, Phase II Study of Pembrolizumab in Combination With Neo Adjuvant EC-Paclitaxel Regimen in HER2-Negative Inflammatory Breast Cancer

Cited by 6 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Nanoparticle albumin-bound paclitaxel-based neoadjuvant regimen: A promising treatment option for HER2-low-positive breast cancer;Nanomedicine: Nanotechnology, Biology and Medicine;2023-04

2. Volume change rate before and after neoadjuvant systemic therapy of breast cancer is an efficacious evaluation index to predict pathological complete response;Frontiers in Oncology;2023-02-06

3. Integration of radiogenomic features for early prediction of pathological complete response in patients with triple-negative breast cancer and identification of potential therapeutic targets;Journal of Translational Medicine;2022-06-07

4. Efficacy and Safety of Albumin-bound Paclitaxel Versus Solvent-based Paclitaxel in Breast Cancer: A Meta-analysis;Journal of Modern Nanotechnology;2022-06-02

5. Nanoparticle albumin-bound paclitaxel is superior to liposomal paclitaxel in the neoadjuvant treatment of breast cancer;Nanomedicine;2022-04